AgomAb Therapeutics NV AGMB
Regular-session close
After hours · Nov 19, 4:24 PM ET
- YTD
- -61.64%
- 1 year
- -61.64%
Fundamental scorecard
3 of 25 checks passed on AGMB’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Value 0 of 5
- Failed:P/E below its own 5-year median No profit over FY 2025, so no P/E.
- Failed:P/E under 20 No profit over FY 2025, so no P/E.
- Failed:Price to sales below its own 5-year median Not enough data to decide.
- No data:Price to book below its own 5-year median Price to book 0.9. Not enough data to decide.
- Failed:Free cash flow yield above 4% Free cash flow of -51.7M is -21.3% of the market value.
Growth 0 of 5
- No data:Revenue grew over the last year Not enough data to decide.
- No data:Revenue grew more than 5% a year over five years Not enough data to decide.
- Failed:Earnings per share grew over the last year EPS -6.60 against -4.95 in the year before.
- No data:Earnings per share grew more than 5% a year over five years Not enough data to decide.
- No data:Analysts expect higher earnings per share over the next year No analyst estimate.
Profitability 0 of 5
- Failed:Profitable over the last year Net income of -62.5M over FY 2025.
- No data:Profitable in each of the last five fiscal years Not enough data to decide.
- Failed:Return on equity above 15% Return on equity of -27.6%.
- No data:Net margin above its 5-year average Not enough data to decide.
- Failed:Free cash flow is at least 80% of net income No profit over FY 2025 to compare with.
Financial health 3 of 5
- Passed:Short-term assets cover short-term liabilities Short-term assets of 258M against short-term liabilities of 20.1M.
- Passed:Short-term assets cover long-term liabilities Short-term assets of 258M against long-term liabilities of 5.48M.
- Passed:Net debt under 40% of equity More cash than debt: 252M of cash against 1.14M of debt.
- Failed:Operating cash flow covers at least 20% of debt Operating cash flow of -51.7M is -4542.7% of debt.
- Failed:Operating profit covers interest at least 3 times Operating profit is -469.3 times the interest expense.
Dividend 0 of 5
- Failed:Pays a dividend No dividend paid.
- Failed:Yield above 1.5% No dividend paid.
- Failed:Pays out under 75% of profit No dividend paid.
- Failed:Covered by free cash flow No dividend paid.
- Failed:Not cut in the last five fiscal years No dividend paid.
Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell. Amounts are in the company’s reporting currency.
Included in Essentials and up
Sign in to see Fair value
Discounted cash flow estimates against the price, and the P/E against its industry and sector.
Included in Essentials and up
Sign in to see Head count and owner earnings
Employees by annual report and the cash the business earns for its owners.
Included in Essentials and up
Sign in to see P/E against peers
The price to earnings ratio beside the closest competitors and their median.
Financial position
What AGMB owns and owes, as of Jun 30, 2026
Short term and long term
Balance sheet · 291M of assets
Debt, equity and cash by year
Now: 251M more cash than debt
Fiscal years, then the newest quarter. Cash includes short-term investments.
From the company’s SEC filings, in its reporting currency.
Included in Essentials and up
Sign in to see Cash flow and returns
How profit turns into free cash flow, and the returns on equity, assets and capital.
Financial health
Rating
C2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 1
Valuation
Profitability
Growth (YoY)
Financial Health
Dividends
Annual · latest fiscal year ends 2025-12-31
